FBXO21 and acute myeloid leukemia: Similar to shFBXO21 KD, Selonsertib treatment led to decreased proliferation, increased apoptosis, but did not demonstrate the same cell surface phenotype as shFBXO21 KD further supporting ASK1 is not likely a substrate of FBXO21 in the context of AML (Supplementary Fig. 2B, F).